Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid Leukemia

被引：11
|
作者：
Zeidan, Amer M. [1 ,2 ]
Schuster, Michael W. [3 ]
Krauter, Jurgen [4 ]
Maertens, Johan A. [5 ]
Gyan, Emmanuel [6 ]
Joris, Magalie [7 ]
Menne, Tobias F. [8 ]
Vyas, Paresh [9 ]
Ma, Weidong Wendy [10 ]
O'Connell, Ashleigh [10 ]
Zeremski, Mirjana [10 ]
Kudla, Arthur [10 ]
Chan, Geoffrey
Sekeres, Mikkael A. [11 ]
机构：
[1] Yale Sch Med, New Haven, CT USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Stony Brook Univ Hosp, Canc Ctr, Stony Brook, NY USA
[4] Med Klinikum Braunschweig GmbH, Dept Internal Med 3, Braunschweig, Germany
[5] UZ Leuven, Leuven, Belgium
[6] CHU Tours, Hop Bretonneau, Tours, France
[7] CHU Amiens Picardie, Amiens, France
[8] Newcastle Upon Tyne Hosp NHS Fdn Trust, Freeman Hosp, Dept Haematol, Newcastle Upon Tyne, Tyne & Wear, England
[9] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England
[10] Pfizer Oncol, New York, NY USA
[11] Cleveland Clin, Leukemia Program, Cleveland, OH 44106 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-124034
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3916
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
    Cortes, Jorge E.
    Heidel, Florian H.
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Montesinos, Pau
    Candoni, Anna
    Leber, Brian
    Sekeres, Mikkael A.
    Pollyea, Daniel A.
    Ferdinand, Roxanne
    Ma, Weidong Wendy
    O'Brien, Thomas
    O'Connell, Ashleigh
    Chan, Geoffrey
    Heuser, Michael
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2020, 13 (01)
  • [2] Survival outcomes and clinical benefit in patients with acute myeloid leukemia treated with glasdegib and low-dose cytarabine according to response to therapy
    Jorge E. Cortes
    Florian H. Heidel
    Walter Fiedler
    B. Douglas Smith
    Tadeusz Robak
    Pau Montesinos
    Anna Candoni
    Brian Leber
    Mikkael A. Sekeres
    Daniel A. Pollyea
    Roxanne Ferdinand
    Weidong Wendy Ma
    Thomas O’Brien
    Ashleigh O’Connell
    Geoffrey Chan
    Michael Heuser
    Journal of Hematology & Oncology, 13
  • [3] Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
    Andrius Zucenka
    Kazimieras Maneikis
    Birute Pugaciute
    Ugne Ringeleviciute
    Austeja Dapkeviciute
    Linas Davainis
    Guoda Daukelaite
    Paulina Burzdikaite
    Vytautas Staras
    Laimonas Griskevicius
    Annals of Hematology, 2021, 100 : 1195 - 1202
  • [4] Glasdegib in combination with low-dose Cytarabine for the outpatient treatment of relapsed or refractory acute myeloid leukemia in unfit patients
    Zucenka, Andrius
    Maneikis, Kazimieras
    Pugaciute, Birute
    Ringeleviciute, Ugne
    Dapkeviciute, Austeja
    Davainis, Linas
    Daukelaite, Guoda
    Burzdikaite, Paulina
    Staras, Vytautas
    Griskevicius, Laimonas
    ANNALS OF HEMATOLOGY, 2021, 100 (05) : 1195 - 1202
  • [5] An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
    Othman, Tamer A.
    Tenold, Matthew E.
    Moskoff, Benjamin N.
    Azenkot, Tali
    Jonas, Brian A.
    EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (05) : 407 - 417
  • [6] Comparative effectiveness of glasdegib versus venetoclax combined with low-dose cytarabine in acute myeloid leukemia
    Tremblay, Gabriel
    Daniele, Patrick
    Bell, Timothy
    Chan, Geoffrey
    Brown, Andrew
    Cappelleri, Joseph C.
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (07) : 603 - 612
  • [7] Budget Impact of Glasdegib in Combination with Low-Dose Cytarabine for the Treatment of First-Line Acute Myeloid Leukemia in the United States
    Ha Anh Pham
    Milev, Sandra
    Li, Shujun
    Zou, Denise
    Hu, Yannan
    Heeg, Bart
    Bell, Timothy J.
    BLOOD, 2019, 134
  • [8] A phase I/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome
    Swaminathan, Mahesh
    Kantarjian, Hagop M.
    Levis, Mark
    Guerra, Veronica
    Borthakur, Gautam
    Alvarado, Yesid
    DiNardo, Courtney D.
    Kadia, Tapan
    Garcia-Manero, Guillermo
    Ohanian, Maro
    Daver, Naval
    Konopleva, Marina
    Pemmaraju, Naveen
    Ferrajol, Alessandra
    Andreeff, Michael
    Jain, Nitin
    Estrov, Zeev
    Jabbour, Elias J.
    Wierda, William G.
    Pierce, Sherry
    Pinsoy, Maria Rhona
    Xiao, Lianchun
    Ravandi, Farhad
    Cortes, Jorge E.
    HAEMATOLOGICA, 2021, 106 (08) : 2121 - 2130
  • [9] LOW-DOSE CYTARABINE IN ACUTE MYELOID-LEUKEMIA
    MANOHARAN, A
    LEYDEN, MJ
    SULLIVAN, J
    MEDICAL JOURNAL OF AUSTRALIA, 1984, 141 (10) : 643 - 646
  • [10] Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial
    Heuser, Michael
    Fiedler, Walter
    Sekeres, Mikkael A.
    Montesinos, Pau
    Leber, Brian
    Merchant, Akil
    Papayannidis, Cristina
    Perez-Simon, Jose A.
    Hoang, Caroline J.
    Ma, Weidong Wendy
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    Cortes, Jorge E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S231 - S231
12345